You searched for united kingdom - Page 5 of 6

Interview 26 Oct 2017

Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses

Serial entrepreneur John Beadle is now at the helm of PsiOxus, an Oxford biotech with some promising virus-based cancer treatments. Oncolytic viruses have been around for a while without much to show for themselves besides Amgen’s Imlygic, but PsiOxus, one of our top Oxford biotechs, has some ideas to make them bear fruit. The company […]

October 26, 2017 - 8 minutesmins - By Evelyn Warner

News and Trends 28 Sep 2017

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing one-shot gene therapies for various eye diseases that could lead to blindness. This morning, it debuted on the Nasdaq with a projected $75M (£56M / €64M) […]

September 28, 2017 - 2 minutesmins - By Evelyn Warner

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

Circassia pharmaceuticals astrazeneca pulmonary disease

News and Trends 7 Sep 2017

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has reported a Phase III success with Duaklir, a drug combination for the treatment of chronic obstructive pulmonary disease (COPD). The trial was run by AstraZeneca, […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 9 Aug 2017

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory epilepsy with focal seizures had not met any of its endpoints in a Phase II […]

August 9, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 28 Jul 2017

Things are Looking Up for UK Synbio Clusters, says Report

A survey of synbio startups in the last 16 years shows that the UK ecosystem is growing rapidly and approaching critical mass, says SynbiCITE. Dedicated to championing industrial uptake of synthetic biology, SynbiCITE is a knowledge center based at Imperial College London. Some of its initiatives have included opening a gene foundry last year to providing grants to […]

July 28, 2017 - 3 minutesmins - By Denise Neves Gameiro

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […]

July 25, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 24 May 2017

UK biotech is catching up to the US, but will it run out of gas?

The UK is far ahead of its European biotech rivals according to a new report, but will it fulfill its promise of becoming a global hub? According to analysis by the BioIndustry Association, the UK is catching up to global biotech leaders San Francisco and Boston, both in finance and R&D. British biotechs banked £1.13B last year, and […]

May 24, 2017 - 5 minutesmins - By Evelyn Warner

abcam axiomx acquisition milestone antibody

More News! 18 May 2017

Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech

Abcam has paid US-based AxioMx a final €4.5M milestone based on performance, completing an acquisition that totals €36.4M. Giant antibody maker Abcam, founded by star biotech entrepreneur Jonathan Milner and based in Cambridge, has announced it made the last payment part of its acquisition deal with AxioMx. The deal was initiated in November 2015 with a […]

May 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 27 Mar 2017

Meet one of the Most Successful Biotech Entrepreneurs in the UK

Jonathan Milner is a rockstar biotech entrepreneur and founder of Abcam. He is still on the board of his baby Abcam, while investing in many young startups, nurturing the British biotech ecosystem and taking part in philanthropy. Here’s my chat with him on all these topics. “I was amazed by how you could order books […]

March 27, 2017 - 7 minutesmins - By Philip Hemme

Congenica Sapientia fundraising clinical genomics e1487935960201

More News! 27 Feb 2017

Fundraising in the UK will Support Rare Disease Diagnostics Worldwide

Congenica has raised £8M in its Series B financing round to sustain the international rollout of its clinical genome analysis platform Sapientia. Congenica is a genomic diagnostics company in Cambridge’s biotech cluster. Its genome analysis platform, Sapientia, takes on the challenge of interpreting the avalanche of genomic data becoming available in healthcare. The £8M (€9.5M) raised will sustain the […]

February 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Feb 2017

Roche doubles down in Fight against Antibiotic Resistance

In 2014, Discuva partnered up with Roche to develop new antibiotics against multidrug-resistant bacteria. The two companies have announced an extension of their collaboration until February 2018. The Cambridge-based company Discuva wants to address the critical need for new antibiotic drugs to treat infections from multidrug-resistant bacteria. Posing a major public health threat, antibiotic resistances cause at least 25,000 deaths per year in […]

February 22, 2017 - 2 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us